CompletedNot applicableNCT06234813
Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study
Studying Glanzmann thrombasthenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Bordeaux
- Principal Investigator
- Mathieu FIOREUniversity Hospital, Bordeaux
- Intervention
- Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen(other)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2023
Study locations (1)
- CHU Bordeaux - Laboratoire Hématologie, Bordeaux, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06234813 on ClinicalTrials.govOther trials for Glanzmann thrombasthenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07136857Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)Emory University
- RECRUITINGNCT06820515ATHNdataset RegistryAmerican Thrombosis and Hemostasis Network
- RECRUITINGNANCT04119908Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic DiseasesUniversity Hospital, Lille
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06211634A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann ThrombastheniaHemab ApS
- RECRUITINGNCT00230165The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.Rockefeller University